INT121514

From wiki-pain
Revision as of 04:30, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.25
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 12
Disease Relevance 4.77
Pain Relevance 0.58

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transferase activity, transferring glycosyl groups (A4GALT) Golgi apparatus (A4GALT) plasma membrane organization (A4GALT)
Anatomy Link Frequency
kidney 2
cardiomyocytes 1
interstitial cells 1
brain 1
urine 1
A4GALT (Homo sapiens)
Pain Link Frequency Relevance Heat
Central nervous system 12 74.72 Quite High
palliative 6 58.88 Quite High
cva 36 39.20 Quite Low
imagery 138 34.80 Quite Low
Pain 180 18.64 Low Low
depression 48 5.00 Very Low Very Low Very Low
fibrosis 42 5.00 Very Low Very Low Very Low
Neuropathic pain 24 5.00 Very Low Very Low Very Low
aspirin 24 5.00 Very Low Very Low Very Low
rheumatoid arthritis 18 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Proteinuria 126 92.16 High High
Disease 324 91.80 High High
Renal Disease 162 82.96 Quite High
Fabry Disease 1152 82.24 Quite High
Chronic Renal Failure 102 81.76 Quite High
Death 60 72.00 Quite High
Heart Disease 12 70.88 Quite High
Cerebrovascular Disease 6 65.40 Quite High
Left Ventricular Hypertrophy 96 55.68 Quite High
Hypertrophy 18 42.48 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Complete clearance of Gb3 was also observed in mesangial and interstitial cells in the majority of patients [357].
Localization (clearance) of Gb3 in interstitial cells
1) Confidence 0.25 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 0.29 Pain Relevance 0
The deficiency leads to progressive glycosphingolipid globotriaosylceramide (Gb3) accumulation in fluids and tissues, including vascular endothelium, connective tissue, kidney, heart, brain and peripheral nerves.
Localization (accumulation) of Gb3 in heart
2) Confidence 0.25 Published 2004 Journal J. Nephrol. Section Abstract Doc Link 15365954 Disease Relevance 0.55 Pain Relevance 0.10
No clearance of Gb3 was observed in the cardiomyocytes during the trial [359].
Localization (clearance) of Gb3 in cardiomyocytes
3) Confidence 0.24 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 0 Pain Relevance 0
Urinary Gb3 excretion was reduced in both studies after 20 weeks of therapy [323,358].
Localization (excretion) of Gb3
4) Confidence 0.23 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 0 Pain Relevance 0
Clearance of Gb3 from renal cells, urine and cardiac cells
Localization (Clearance) of Gb3 in urine
5) Confidence 0.22 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 0.52 Pain Relevance 0
Progressive Gb3 clearance from podocytes was observed on kidney biopsies (n = 8) after 54 months of ERT (Figure 30) [309].
Localization (clearance) of Gb3 in kidney
6) Confidence 0.22 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 0.44 Pain Relevance 0
Alpha-galactosidase A antibodies frequently developped in male patients (18/28) and interfered with urinary Gb3 excretion.
Localization (excretion) of Gb3
7) Confidence 0.22 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 0.22 Pain Relevance 0
The deficiency leads to progressive glycosphingolipid globotriaosylceramide (Gb3) accumulation in fluids and tissues, including vascular endothelium, connective tissue, kidney, heart, brain and peripheral nerves.
Localization (accumulation) of Gb3 in brain
8) Confidence 0.08 Published 2004 Journal J. Nephrol. Section Abstract Doc Link 15365954 Disease Relevance 0.55 Pain Relevance 0.10
The deficiency leads to progressive glycosphingolipid globotriaosylceramide (Gb3) accumulation in fluids and tissues, including vascular endothelium, connective tissue, kidney, heart, brain and peripheral nerves.
Localization (accumulation) of Gb3 in peripheral nerves
9) Confidence 0.08 Published 2004 Journal J. Nephrol. Section Abstract Doc Link 15365954 Disease Relevance 0.55 Pain Relevance 0.10
The deficiency leads to progressive glycosphingolipid globotriaosylceramide (Gb3) accumulation in fluids and tissues, including vascular endothelium, connective tissue, kidney, heart, brain and peripheral nerves.
Localization (accumulation) of Gb3 in vascular endothelium
10) Confidence 0.08 Published 2004 Journal J. Nephrol. Section Abstract Doc Link 15365954 Disease Relevance 0.55 Pain Relevance 0.10
The deficiency leads to progressive glycosphingolipid globotriaosylceramide (Gb3) accumulation in fluids and tissues, including vascular endothelium, connective tissue, kidney, heart, brain and peripheral nerves.
Localization (accumulation) of Gb3 in connective tissue
11) Confidence 0.08 Published 2004 Journal J. Nephrol. Section Abstract Doc Link 15365954 Disease Relevance 0.55 Pain Relevance 0.10
The deficiency leads to progressive glycosphingolipid globotriaosylceramide (Gb3) accumulation in fluids and tissues, including vascular endothelium, connective tissue, kidney, heart, brain and peripheral nerves.
Localization (accumulation) of Gb3 in kidney
12) Confidence 0.08 Published 2004 Journal J. Nephrol. Section Abstract Doc Link 15365954 Disease Relevance 0.55 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox